New phase IIIB data shows Novartis Fabhalta improved haemoglobin levels in adult patients with PNH who switched from anti-C5 therapy: Basel Saturday, December 7, 2024, 10:00 Hrs [ ...
Analysis of Bausch + Lomb Corporation's debt issues, Bausch Health Companies Inc.'s Q3 results, and strategies to overcome ...
Promising topline results from a phase 3B study show the efficacy and quality of life (QOL) improvements of iptacopan ...
Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and ...
Veeva Europe president Chris Moore talks about the company’s new genAI-powered releases and its move from Salesforce to a ...
Local Spotlight: Managing high bad cholesterol. High bad cholesterol is a risk factor for a common type of heart disease, yet ...
That’s according to the latest data from real-time ad trackers iSpot.TV. Their analysts found AbbVie’s immunology drug duo ...
One of the impacted factories, Dura Supreme in Statesville, opened last year. Dura Supreme started as a family-run business ...
Novartis (NVS) announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral ...
Analyst Joseph Schwartz from Leerink Partners reiterated a Hold rating on PTC Therapeutics (PTCT – Research Report) and increased the price ...
President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...